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Abstract: Stretching the alveolar epithelial type I (AT I) cells controls the intercellular signaling for the
exocytosis of surfactant by the AT II cells through the extracellular release of adenosine triphosphate
(ATP) (purinergic signaling). Extracellular ATP is cleared by extracellular ATPases, maintaining its
homeostasis and enabling the lung to adapt the exocytosis of surfactant to the demand. Vigorous
deformation of the AT I cells by high mechanical power ventilation causes a massive release of
extracellular ATP beyond the clearance capacity of the extracellular ATPases. When extracellular
ATP reaches levels >100 µM, the ATP receptors of the AT II cells become desensitized and surfactant
impairment is initiated. The resulting alteration in viscoelastic properties and in alveolar opening and
collapse time-constants leads to alveolar collapse and the redistribution of inspired air from the alveoli
to the alveolar ducts, which become pathologically dilated. The collapsed alveoli connected to these
dilated alveolar ducts are subject to a massive strain, exacerbating the ATP release. After reaching
concentrations >300 µM extracellular ATP acts as a danger-associated molecular pattern, causing
capillary leakage, alveolar space edema, and further deactivation of surfactant by serum proteins.
Decreasing the tidal volume to 6 mL/kg or less at this stage cannot prevent further lung injury.
Keywords: extracellular ATP; purinergic signaling; P2X receptors; P2Y receptors; surfactant dysfunction;
ventilation-induced lung injury; innate immunity
Int. J. Mol. Sci. 2018, 19, 1185; doi:10.3390/ijms19041185 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2018, 19, 1185 2 of 19
1. Introduction
In 1929, Lohmann discovered and isolated adenosine triphosphate (ATP) from liver and muscles [1,2].
ATP is widely known as an intracellular molecule that is able to transfer energy and is indispensable in
living cells [3,4]. Much later, extracellular ATP was identified and appeared to have a different function
than the intracellularly located molecule. The intercellular signaling function of extracellular ATP has
been described by Felberg and Hebb in 1948 in perfused cervical superior ganglion of the cat [5] and
by Holton in 1959 in the sensory nerves of the rabbit ear [6]. In 1972 Burnstock wrote an article on
the hypothesis of the purinergic co-transmission in neurons [7]. However, it took more than 20 years
before the intracellular energy source ATP was recognized as an extracellular signaling molecule [8].
Now ATP is established as an important element of purinergic signaling in almost all tissues and the
immune system [9].
It is well documented that potentially lifesaving mechanical ventilation may ironically damage
the lungs and increase mortality risk in patients with acute respiratory distress syndrome (ARDS) by
causing ventilation-induced lung injury (VILI) [10–13] and ARDS remains a serious clinical problem
with mortality close to 40% [14]. Gattinoni, et al. (2016) found that it was not just the individual
components of the mechanical breath (i.e., tidal volume, respiratory rate, driving pressure and positive
end expiratory pressure—PEEP) that cause VILI but rather the mechanical power that the combination
of these components generate [11]. Using continuous mandatory ventilation (CMV—volume control
ventilation) with a tidal volume of 38 mL/kg (corresponding to a strain of 2.5). Cressoni, et al. (2016)
reported that, in piglets, lung injury cannot be provoked at a respiratory rate of≤9/min corresponding
to a mechanical power of <12 J/min [15]. Mechanical power of the ventilator is calculated by a
formula. Tidal volume, respiratory system elastance, inspiratory-to-expiratory time ratio, airway
resistance, respiratory rate and PEEP are include in the equation of the formula [11]. High power
mechanical ventilation is defined as any mechanical breath, which exceeds 12 J/min and corresponds
to a mechanical ventilation settings with a tidal volume of >38 mL/kg ideal body weight and a
respiratory rate of ≥12/min [15]. Reportedly, intratracheal administration of 400 µL of 5.16 mM
ATP in rats leads to alveolar edema [16] and intratracheal instillation of 50 µL of 100 mM ATP or
200 mM uridine triphosphate (UTP) in mice leads to diffuse alveolar damage resembling the effect of
high power mechanical ventilation [17]. Recently, we reported that injurious mechanical ventilation
results in vigorous cyclic mechanical deformations of the alveolar epithelial cells resulting in massive
release of extracellular ATP from the alveolar epithelial type I (AT I) cell [10]. The high levels of
extracellular ATP activate a pro-inflammatory immune response of the innate immune system through
purinergic signaling [18–20] which causes diffuse alveolar damage (DAD) [10,17], the histopathology
characteristic of VILI [21].
In this report, we centered on an important component of VILI: the impairment of the pulmonary
surfactant function [22,23]. Multiple mechanisms for VILI-induced surfactant impairment in the
absence of infection have been reported: (1) increased pulmonary vascular permeability resulting
in pulmonary edema with high serum proteins. These serum proteins cause disaggregation and
inactivation of surfactant [24], reducing the proportion of functional large aggregates (LAs) significantly
in favor of the non-functional small aggregates (SAs) [22,23]; (2) High mechanical power ventilation
may enhance the transport of alveolar surfactant into the airways [25,26]. However, these explanations
do not account for the mechanism of increased surfactant in the lung lavage in the first two hours
during mechanical ventilation with high mechanical power [22,27]. Additionally, the pathogenesis of
VILI suggests a mechanism other than capillary leak as the initiating event: High mechanical power
ventilation in rats causes surfactant composition changes with surfactant function impairment within
one hour and a fall in lung compliance occurs within two hours [22], whereas capillary leak causing
overt alveolar edema detected by a computed tomography (CT) scan does not develop for 2–14 h [28]
and histological evidence of alveolar edema was not detected at two hours [29].
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Therefore, we searched and studied the literature elaborately to find the explanation for the
increased surfactant production and the development of surfactant impairment that precede the
capillary leak, lung edema and the pro-inflammatory response of the innate immune system.
2. Extracellular Release of ATP by AT I and AT II Cells and Clearance of Extracellular ATP
In contrast to the relatively high (3 to 10 mM) intracellular concentrations of ATP in epithelial
cells [30] the concentration of extracellular ATP in the medium around the 6HBE14o– human bronchial
epithelial cells [31] and in resting conditions measured in a cell culture of rat AT II cells [32] is much
lower at about 2 nM (Figure 1A). Mechanical deformation (tonic or cyclic stretching) during ventilation
of the AT I cells activates the mechanosensitive P2X7 ATP receptors (P2X7Rs) causing a controlled
extracellular release of ATP molecules (Figure 1B) [32,33]. In this case the P2X7Rs function as an ATP
release channel [34] rather than an intrinsic cation channel or an ATP receptor initiating intracellular
signal transduction (P2Y2R and P2X4R in Figure 1B).
Extracellular ATP molecules are converted by ATP-converting ecto-enzymes or by soluble
extracellular enzymes to adenosine (Figure 1A–C) [10,18]. The hydrolyzing enzymes are: Nucleoside
triphosphate diphosphohydrolase 1 (NTPD1 or CD39, converts ATP to ADP and ADP to AMP),
nucleotide pyrophosphatase/phosphodiesterase (NPP, converts ATP to AMP) and 5′-nucleotidase
(5′-NT or CD73, converts AMP to adenosine). Soluble extracellular adenosine deaminase (ADA)
converts a proportion of extracellular adenosine to inosine. The remaining adenosine molecule enters
the cells via the equilibrative nucleoside transporters (ENT1 and ENT2) and concentrative nucleoside
transporters (CNT1 and CNT2). Intracellular adenosine is converted to inosine, hypoxanthine, and
AMP by the enzymes ADA, purine nucleoside phosphorylase (PNP) and adenosine kinase (ADK).
This process maintains the homeostasis of extracellular ATP in the alveolar walls (Figure 1A–C [10,18].
Figure 1. Cont.
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Figure 1. Schematic presentation of the regulation of surfactant exocytosis. For greater clarity, the high
cytosolic adenosine triphosphate (ATP) content is omitted in the figure. (A) Resting state of the
alveolar epithelial type I (AT I) and AT II cells. (B) ATP-induced fusion- activated calcium-ion
entry resulting in surfactant exocytosis. (C) Excessive extracellular ATP concentrations causing the
impairment of surfactant exocytosis. See text for explanation. AT I: Alveolar epithelial type I cell; AT II:
Alveolar epithelial type II cell; ER: Endoplasmic reticulum; LB: Lamellar body; P2Y2R and P2X4R:
ATP receptors; Gq/11: G protein-coupled receptor molecules comprising αi and βγ subunits; PLC-β:
Phospholipase C beta; PIP2: Phosphatidylinositol 4,5-bisphosphate; IP3: Inositol triphosphate; IP3R:
Inositol triphosphate receptor, a membrane bound glycoprotein complex functioning as a Ca2+ channel
sensitive to activation by IP3; STIM1: Stromal interaction molecule 1, a calcium sensor; Orai1: Calcium
release-activated calcium channel protein 1, a calcium selective ion channel; TRPV2: Transient receptor
potential cation channel subfamily V member 2, a non-selective cation channel; Kir3: K+ selective
inwardly rectifying channel 3 or GIRK2: G protein-coupled inwardly-rectifying K+ channel 2; DAG:
diacylglycerol; PKC: protein kinase C; CD39: Nucleoside triphosphate diphosphohydrolase 1 (NTPD1);
NPP: nucleotide pyrophosphatase/phosphodiesterase; CD73: 5′-nucleotidase (5′-NT); ADA: adenosine
deaminase; ENTs: Equilibrative nucleoside transporters 1 and 2; CNTs: Concentrative nucleoside
transporters 1 and 2; FACE: fusion-activated Ca2+ entry; SERCA: sarcoplasmic/endoplasmic reticulum
Ca2+ ATPase channel; PMCA: Plasma membrane Ca2+ ATPase channel. Figures extensively adapted
from Hasan, et al. (2017) [10] (open access) with permission.
3. Purinergic Signaling Increases the AT II Cytoplasmic Ca2+ Levels by the Entry of Extracellular
Ca2+ and Store-Operated Ca2+ Entry (SOCE)
The extent of the extracellular release of ATP molecules by cyclic stretching of the lung
is proportional to the strain (equivalent to the tidal volume), frequency and duration of the
ventilation [32,33]. When the extracellular ATP concentrations reach the half maximum effective
concentration (EC50) of 85 to 230 nM in human [35], ATP binds to and activates the P2Y2Rs at the AT II
cell membranes (Figure 1B) [36]. This facilitates the coupling of the Gq/11 molecule (comprising αi
and βγ subunits) to the G protein-coupled receptor (GPCR) structure of the P2Y2Rs. In the basal state,
the heteromeric Gq/11 subunits are indissoluble. After coupling to the GPCR, Gq/11 subunits are
activated. The activated αi subunit releases a guanosine 5′-diphosphate (GDP) molecule and binds to
a guanosine 5′-triphosphate (GTP) molecule followed by the dissociation of the αi and βγ subunits
initiating intracellular signal transduction [37]. The αi and βγ subunits activate phospholipase C beta
(PLC-β) to hydrolyze phosphatidylinositol 4,5-bisphosphate (PIP2) resulting in the formation of the
second messengers diacylglycerol (DAG) and inositol triphosphate (IP3) [38]. IP3 binds with the IP3
receptors (IP3Rs, a membrane-bound glycoprotein complex functioning as a Ca2+ channel sensitive
to activation by IP3) causing the release of Ca2+ by the endoplasmic reticulum (ER). This process
is referred to as store-operated Ca2+ entry (SOCE). IP3Rs are important calcium release channels
of SOCE [39]. The ryanodine receptor (another important SOCE Ca2+ release channel in skeletal
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muscle, smooth muscle, and cardiac muscle) is not expressed in the lung tissue [40]. SOCE causes
Ca2+ store depletion that is sensed by the EF-hand and sterile α motif (EF-SAM) regions of Stromal
interaction molecule 1 (STIM1, a calcium sensor). This information is transferred to activate the plasma
membrane STIM1 Orai1-activating region/CRAC-activating domain (SOAR/CAD) regions through
the cytoplasmic C-terminus 1 (CC1) regions of the STIM1 molecules located in the cytoplasm. Then
the SOAR/CAD regions activate the calcium release-activated calcium channel protein 1 (Orai1) Ca2+
channels at the plasma membrane allowing extracellular Ca2+ molecules to enter the cytoplasm. STIM1
and Orai1 belong to the calcium release-activated calcium channel (CRAC) family (Figure 1B) [39].
Inward Ca2+ current is also generated though the mechanosensitive transient receptor potential
cation channel subfamily V member 2 (TRPV2, a non-selective cation channel) during inspiration [41].
In addition, the Gqβγ subunits of the activated P2Y2Rs simulate (by a direct binding) the K+ selective
inwardly rectifying channel 3 (Kir3) or G protein-coupled inwardly-rectifying K+ channel 2 (GIRK2)
expressed on the AT II cell membrane [37]. Kir3 or GIRK2 is a mechanosensitive channel and can
also be activated by mechanical deformation of the AT II cells (Figure 1B) [42]. Moreover, activation
of the P2Y2Rs and the P2X4Rs induces the volume-regulated anion current channel (VRAC). One of
the major components of VRAC is the outwardly rectifying Cl– channel that is sensitive to protein
kinase C (PKC) activation [43,44]. DAG, phosphatidylserine (Ptd-Ser, a component of the AT II cell
membrane) and Ca2+ are required for the activation of PKC. DAG strikingly increases the affinity
of PKC for Ca2+ [45]. PKC binds with Ca2+ exposing a binding site for Ptd-Ser of the inner part of
the cell membrane leading to a redistribution of PKC from the cytosol to the cell membrane [45].
This promotes the trafficking of the lamellar bodies (LBs), docking hemifusion and fusion of the LB
membrane with the plasma membrane of the AT II cell (Figure 2A) [46]. After the development of a
fusion pore, further pore expansion is accelerated by an additional elevation of cytoplasm Ca2+ levels
resulting in the exocytosis of surfactant. It was first thought that the additional elevation in Ca2+ levels
is achieved by extracellular ATP molecules that reach the P2X4Rs located at the LB membrane through
the newly formed fusion pore [47,48]. But recently, it appeared that the LBs of rat AT II cells contains a
high ATP level of about 1.9 mM at a low pH of 5.5 [49]. ATP is transported from the cytosol to the LBs
through the vesicular nucleotide transporter (VNUT) located on the LB membrane [50,51]. P2X4Rs are
inwardly rectifying cation (Na+ and Ca2+) channels located at the membrane of the LBs (Figure 1B) [49].
At pH values lower than 7.4 [49] and at ATP concentrations >100 µM [52] the P2X4Rs are desensitized.
Because the fusion pore connects the intravesicular space of the LBs with the extracellular space with a
pH value of 7.4 and with low ATP concentrations, the intravesicular pH increases to 7.4 and ATP is
released from the LBs to the extracellular space. This causes the intravesicular ATP levels to fall from
1.9 mM to 1–5 µM and within the window of the effective concentrations of the P2X4Rs (as shown in in
human embryonic kidney 293—HEK293—cells [52]). This renders the P2X4Rs to become resensitized
to ATP stimulation allowing Ca2+ ions to enter the cytoplasm (Figure 1B) [52,53].
In addition, IP3 can be transported from AT II to other AT II cells, but direct communication
between AT II cells can occur only by bridging the AT I cells that separate the AT II cells by means
of tunneling nanotubes (TNTs) [54]. TNTs are long membrane projections with a diameter of 50 to
200 nM and a length of up to ~70 µM (the size of several cells) [55]. TNTs are capable of transporting
signals, organelles, and viruses between AT II cells in the presence of connexin gap junction protein
isoform 43 (Cx43) [54]. Reportedly, both Cx43 and TNTs are expressed by the AT II cells [56] and
intercellular communication through TNTs between alveolar AT II cells that express Cx43 can induce
intercellular Ca2+ waves by the transmission of IP3 molecules [54]. This process and the activities of
outwardly rectifying Cl– channels and G protein-coupled inwardly-rectifying K+ channels 2 (GIRK2)
reinforce the increase of AT II cytoplasmic Ca2+ levels through the paracrine stimulation of the P2Y2Rs
by extracellular ATP and the autocrine stimulation of P2X4Rs by vesicular ATP (Figure 1B).
The time required for the LB fusion after the activation of the P2Y2Rs ranges from seconds to
several minutes [46]. After the initial fusion pore has developed, a perivesicular F-actin coating is
formed around the fused LBs (Figure 2A). This process is Ca2+-dependent [57]. Despite the accelerated
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increase in cytoplasm Ca2+ levels, surfactant exocytosis is a relatively slow process (lasting several
minutes to hours) [46,58]. The amount of the released surfactant by the AT II cells is proportional to
the extracellular ATP levels [32].
Figure 2. Schematic presentation of the surfactant homeostasis of the alveolar epithelial cells. (A)
A perivesicular F-actin coating is formed around the fused LBs after the initial LB fusion pore
has developed. Several types of fusion pore development are described [57]: (1) 80% of the
F-actin-coated fused LBs release surfactant and the LB membrane becomes part of the plasma membrane
(kiss-coat-and-release) followed by the disappearance of the F-actin coat; (2) 10% of the F-actin-coated
fused LBs discontinued the fusion process and returned inside the cell (kiss-coat-and-run); (3)
In the remaining F-actin-coated LBs the fusion process was arrested for a certain time (<20 min)
(kiss-coat-and-wait) [57]. The endocytosis of SAs occurs through a clathrin-dependent pathway [59] by
the activation of several types of SP-A receptors [59–63] and a SP-D receptor [64]. The SP-D receptor is
a GPR116, also known as Ig-Hepta that are highly expressed in the lung [64]. Besides SAs uptake, this
process also inhibits the surfactant exocytosis and contributes to the control of extracellular surfactant
homeostasis [59,64]. (B) The activation of the pro-inflammatory response of the innate immune system
through the activation of the P2X7Rs by extracellular ATP at >300 µM concentrations (ATP molecules at
these concentrations act as DAMPs) leads to the recruitment and activation of neutrophils. The recruited
and activated neutrophils cause the degradation of SP-D and SP-A leading to a deficiency of SP-D
and SP-A [65,66] preventing the clathrin-dependent recycling of the majority of SAs and aborting the
above-mentioned inhibition of the trafficking, semi-fusion and fusion of the LBs with the cell membrane.
AT I: Alveolar epithelial type I cell; AT II: Alveolar epithelial type II cell; ER: Endoplasmic reticulum;
LB: Lamellar body; MVB: multivesicular body; SP-A: Surfactant protein A; SP-D: Surfactant protein
D; SAs: Surfactant small aggregates; LAs: Surfactant large aggregates; GPR116: G protein-coupled
receptor 116; DAMPs: danger-associated molecular patterns.
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4. Fusion of Lysosomes and LBs with the Plasma Membrane Plays a Role in the Repair of
Damaged Plasma Membrane of the AT I and AT II Cells, Respectively
Belete, et al. (2011) reported that the repair of damaged rat AT I cell monolayers by applying
stretch assay or micropuncture assay is facilitated by the subsequent increase in extracellular ATP
concentrations. At extracellular concentrations of about 10 µM ATP activates the P2Y2Rs causing the
fusion of the membrane of lysosomes with the plasma membrane releasing the lysosomal-associated
membrane protein 1 (LAMP-1) and replacing the damaged plasma membrane [67]. The application of
apyrase (CD39) that converts ATP to ADP and AMP and after silencing of the expression of P2Y2Rs
the plasma membrane repair rate are reduced significantly [67]. We think that similar repair process of
the AT II plasma membrane may occur following the fusion of LBs with the plasma membrane.
5. FACE Causes a Trans-Epithelial Transport of Na+, Ca2+ and Water Molecules
Besides surfactant exocytosis, FACE causes a trans-epithelial transport of Na+ and Ca2+ molecules
from the alveolar space through the P2X4Rs and the cytoplasm of the AT II cells to the sub-epithelial
interstitial space. This is followed by a passive water resorption from the alveolar liquid lining to the
sub-epithelial interstitial space (Figure 1B). Together with the transepithelial transport of Na+ (through
the epithelial Na+ channel—ENaC) and Cl– (through the cystic fibrosis transmembrane conductance
regulator—CFTR) [68] FACE keeps the alveolar liquid lining as thin as 200 nM with a high density
of surfactant phospholipid membranes [48]. The thin alveolar liquid lining promotes the contact
between the highly organized multilayer surfactant LAs that are stored in the hypophase beneath
the surface active monolayer interfacial film and the surfactant monolayer itself. This facilitates the
adsorption of surfactant from the multilayer LAs to the surfactant monolayer film [48]. The surface
active monolayer interfacial film forms the basis for an optimal diminution of the surface tension of
the air-liquid interface in the alveolar space [69].
6. Surfactant Remodeling in the Alveolar Space
In the alveolar space, surfactant aggregates undergo a remodeling process forming LB-like
surfactant compositions and tubular myelin, a lattice-like arrangement of surfactant phospholipid
molecules with SP-A and SP-B molecules. These highly organized multilayer surfactant LAs in the
extracellular hypophase are thought to be indispensable during the ventilation-induced expansion
(inflation) for the adsorption of the phospholipid molecules to the surface active monolayer film at the
air-liquid interface (interface film layer) in the alveolar space [69]. SP-B and SP-C are indispensable
for the adsorption process [70,71] and this process is followed by the spreading of the surfactant
molecules in the interface film layer [69]. Additionally, the transport of oxygen molecules in a water
layer containing SP-B and SP-C-mediated densely packed lipid membranes is significantly faster than
through a pure water layer or a water layer with pure phospholipid membranes [72].
At the beginning of the ventilation-induced compression (deflation) the surfactant molecules
in the interface film are not densely packed and still have space to condense causing a rather steep
drop in surface tension. Then as deflation progresses the interface monolayer becomes saturated with
phospholipid molecules and starts to collapse forming an inward [73,74] or outward [75] buckling of
surfactant bilayers. The outwardly buckled surfactant molecules form bilayer disks that rest above the
monolayer [75]. These bilayer disks can either be reincorporated into the monolayer [75] or converted
to non-functional SAs and lost into the alveolar space and airways [26,69]. Similarly, part of the
inwardly buckled surfactant bilayers may be reincorporated into the interface monolayer during
the adsorption process or may form new multilayer LAs in the hypophase or may be converted to
non-functional SAs [69].
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7. Surfactant Homeostasis in the Alveolar Space
About 10% of the total surfactant molecules is lost and replenished each hour [69]. A small
proportion (7–15%) is cleared through the airways [25,26,69] presumably after the collapse of the
interface monolayer through outward buckling [75] and 20% is cleared by macrophages promoted
by GM-CSF (granulocyte-macrophage colony stimulating factor) [69]. A very small proportion of
surfactant proteins can be detected in the blood [76], but the majority of the “spent” surfactant (about
65%) is taken up by the AT II cells through endocytosis to be recycled [69]. Under basal conditions, SA
endocytosis is executed through a clathrin-independent pathway [59]. In contrast, in the presence of
secretagogues such as extracellular ATP the uptake of SA is dependent on the clathrin pathway and on
both extracellular SP-A and SP-D levels (Figure 2A) [59].
Several SP-A-binding proteins at the cell membrane of the AT II cells are reported:
(1) SP-A receptors that bind to A2C and A2R monoclonal anti-idiotype antibodies (SPARs) [60];
(2) surfactant-binding protein BP55 [61]; (3) SP-A receptor with a 50-kD protein core that binds
SP-A in a calcium-dependent manner not involving the mannose-binding region of SP-A [62];
(4) a 210-kDa SP-R210 [63]; (5) SP-A receptor that is identified as type II transmembrane protein
p63 (CKAP4/p63) [59]. Additionally, another receptor that is involved in SA endocytosis is reported:
the GPR116 (Figure 2A) [64]. GPR116 is also known as Ig-Hepta which has Ig-like repeats in the
N-terminal extracellular domain and is highly expressed in the lung [64]. GPR116 is thought to be an
orphan GPCR carrying an agonistic protein sequence (Stachel sequence) that functions as a tethered
agonist after the removal or a structural change of the N-terminal from the C-terminal fragment of
the Stachel sequence [77]. Recently, the activation of the GPR116 by synthetic peptides resembling the
C-terminal fragment has been reported [77]. In addition, SP-D may function as a ligand activating the
GPR116 [64]. Increased SP-D levels in the alveolar liquid lining activate GPR116s. Thus SP-A and SP-D
activate the clathrin-dependent ‘spent’ SA uptake and apparently inhibit the exocytosis of surfactant
contributing to the control of extracellular surfactant homeostasis in the alveoli (Figure 2A) [59,64].
8. Clearance of Ca2+ Ions from the Cytoplasm
Clearance of the Ca2+ from the AT II cytoplasm occurs by re-entering the endoplasmic reticulum
(ER) through sarcoplasmic/endoplasmic reticulum Ca2+ ATPase channels (SERCAs) that can transfer
Ca2+ from the cytoplasm to the ER using energy from ATP hydrolysis [78,79] and/or by leaving the
cell through Plasma membrane Ca2+ ATPase channels (PMCAs) that are capable of transferring Ca2+
from the cytoplasm to the extracellular space (Figure 1B) [80]. Isoforms of both SERCA and PMCA
are expressed in the lung [78,80]. Under resting conditions, SERCA is bound to phospholamban
(SERCA-PLB complex) and the ATPase activity is inhibited. Activation of SERCA-PLB complex occurs
after the cytoplasm levels of Ca2+ reach micromolar concentration or after phosphorylation by PKC
followed by a partial dissociation of PLB from SERCA [81]. In contrast, PMCA is active under resting
conditions and is attenuated by activated STIM1 (Figure 1B) [82]. Restored Ca2+ ER levels terminate
the stimulation of STIM1 allowing Ca2+ ions to be released to the extracellular space. Very high activity
of PKC and GIRK2 causes the phosphorylation of the intracellular C-terminal tail of the P2Y2R GPCR
molecules causing the ATP receptor to be desensitized (Figure 1B,C) [83,84]. GIRK2 can be inhibited
by PLCβ through depletion of PIP2 and activation of PKC (Figure 1B) [42]. These processes control the
cytoplasmic Ca2+ levels.
9. Ventilation-Induced Extracellular ATP: (1) Initially Increases the Surfactant Release, (2) Halts
Surfactant Release and Plasma Membrane Repair at >100 µM Concentrations and (3) Triggers the
Pro-Inflammatory Response of the Innate Immunity at >300 µM Concentrations
Mechanical ventilation with high mechanical power (>12 J/min) causes vigorous cyclic
deformation of the AT I and AT II cells followed by an increased release of extracellular ATP [10].
This proportionally increases the release of surfactant [32] and explains the increase in LA levels
in bronchoalveolar lavage fluids (BALFs) in the first hour during ventilation with high mechanical
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power [22]. Martinez, et al. (2004) confirmed the increase in surfactant exocytosis and increase in
respiratory compliance in the first hour of ventilation with high mechanical power in newborn rats [27].
We postulate that after one hour the purinergic receptors of the surfactant release mechanism become
desensitized (Figure 1C). The mechanism for this desensitization could be explained if extracellular
levels of ATP reached ≥100 µM: In-vitro exposure of rat glomerular mesangial cells P2Y2Rs to 100
µM ATP during 2 min decreased the sensitivity to stimuli within 1 min. P2Y2Rs reached their
maximum desensitization to stimuli within 2 to 4 min. Repetitive stimuli with an interval of 7 min.
led to increasingly weaker responses [85]. Desensitization of the P2Y2Rs occurs through two distinct
mechanisms: (1) Phosphorylation of the intracellular C-terminal tail of the P2Y2R GPCR by GIRK2 or by
PKC. This prevents the coupling of Gqα and GqβY subunits to the P2Y2R GPCR [84]; (2) Internalization
of the P2Y2Rs rendering the receptor inaccessible to ATP binding through an unknown pathway [86].
In HEK293 cells desensitization of the P2X4Rs occurs faster within seconds after a stimulus with 100 µM
ATP and being maximally desensitized within 30 to 60 s [52]. The mechanisms of desensitization are: (1)
Allosteric change of the P2X4R molecules decreasing the Ca2+ pore dimensions [53]; (2) Internalization
of the P2X4Rs regulated by Rab5 (a small Ras-like GTPase 5) that promote membrane invagination
leading to the endocytosis of P2X4Rs through the clathrin pathway [87]. After desensitization, these
receptors become unresponsive to ATP stimuli followed by the absence of cytoplasmic Ca2+ response
to mechanical deformation of the AT I and AT II cell abolishing the surfactant exocytosis by the AT
II cells. Therefore, extracellular ATP concentrations >100 µM desensitize the P2Y2Rs at the plasma
membrane of AT II cells and prevent the resensitization of the P2X4Rs in the membrane of LBs leading
to the impairment of the surfactant release to the extracellular space. Diminishing surfactant exocytosis
involves the disappearance of the FACE-induced trans-epithelial transport of Na+, Ca2+ and water
molecules from the alveolar space to the interstitium (Figure 1B,C). Consequently, the thickness of the
alveolar liquid lining increases, reducing the density of surfactant phospholipid membranes in the
hypophase. This diminishes the contact between both the highly organized multilayer surfactant LAs
in the hypophase and the surface active monolayer interfacial film. Obviously, this process contributes
to the impairment of surfactant function. We postulate that in addition to a halt in the fusion process
of LBs with the plasma membrane of AT II cells, the fusion of lysosomes with the plasma membrane of
AT I cells is also inhibited by the desensitization of the P2Y2Rs affecting the capacity of the AT II and
AT I cells to repair plasma membrane damage.
In addition, increasing extracellular ATP levels results in the up-regulation of the ecto-enzymes
and soluble extracellular ATP-converting enzymes CD39 and CD73 leading to a significant increase in
extracellular adenosine levels [88]. However, the massive release of ATP in high mechanical power
ventilation probably exceeds the capacity of these ATP-converting enzymes to convert ATP molecules.
The effective extracellular ATP concentrations to activate the P2X7Rs (in JJ4 macrophage cells and
in HEK cells expressing P2X7Rs) starts at about 300 to 1000 µM, [89]. In contrast to the P2Y2Rs
and P2X4Rs, the P2X7Rs are not subject to desensitization at millimolar or higher extracellular ATP
concentrations [89]. P2X7Rs are located at the cell membranes of many immune cells enabling ATP
molecules to act as danger associated molecular patterns (DAMPs) activating the pro-inflammatory
response of the innate immune system [10,18–20]. The recruited and activated neutrophils degrade
the SP-D and SP-A molecules through a neutrophil serine protease-dependent cleavage and lead
to a deficiency of SP-D and SP-A [65,66]. This prevents the recycling of the majority of SAs
(Figure 2B) [59,64]. Under nanomolar concentrations of extracellular ATP deficiency of SP-A and SP-D
aborts the inhibition of the surfactant exocytosis (Figure 2A). However, at >100 µM extracellular ATP
concentrations the desensitization of the P2Y2Rs and P2X4Rs prevents surfactant release (Figure 2B).
The consequences at this stage are that there is a relative increase of non-functional SAs compared to
functional LAs and a depletion of LAs in the alveolar space.
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10. Surfactant Deactivation Develops Significantly before Alveolar Space Flooding Caused by
Increased Capillary Permeability
As mentioned above, it is generally assumed that alveolar exudate of serum proteins explains
the deactivation of surfactant function [24] and the development of overt lung edema [15]. However,
the group of Lachman (2017) reported that ventilation with high mechanical power for two hours
in rats causes a steady increase in the serum C3a levels and a significant increase in lung weight,
although the histology of the lung tissue revealed characteristics of diffuse lung injury and a profound
interstitial edema they found very little alveolar edema [29]. In addition, Cressoni, et al. (2015) found
that alveolar edema as depicted by serial CT scanning as newly developed densities occurs not earlier
than 2.1 to 14.7 h [28].
We explain this phenomenon by the following consecutive processes: First, because cytokine
levels in mice lung tissue homogenate do not increase earlier than one hour of mechanical
ventilation [90] and because the serum complement C3a levels are increased after one hour of high
power mechanical ventilation [29], we assume that it takes at more than one hour for the extracellular
ATP to reach concentrations >300 µM required to activate the P2X7Rs of the immune cells and initiate
the pro-inflammatory response of the innate immune system. Second, shortly after the activation of the
pro-inflammatory response of the innate immunity, complement components are produced by many
cells of the immune system. Induction of the activity of complement C5a and C3a in-vitro by moderate
concentrations of zymosan (0.01 mg/mL) starts immediately and requires eight hours to reach the
maximum level of activation [91]. The small complement fragments C5a and C3a increase vascular
permeability in rabbit skin causing capillary leakage of fluid leading to interstitial lung edema [92].
Third, the tight junctions between alveolar epithelial cells in the lung (consisting of different types of
claudins, zonula occludens-1, occludin, etc.) are an important barrier against exudate formation in
the alveolar space [93] and claudin-4 and claudin-18 are expressed in the lung tissue [94]. Wray, et al.
(2009) reported that the expression of claudin-4 is increased in the course of three hours of mechanical
ventilation with a tidal volume of 20 mL/kg [95]. Fourth, the transcription, activation and extracellular
release of IL-1β and the IL-1β -dependent production and activation of matrix metalloproteinase 9
(MMP-9) causing the degradation of the tight junctions proteins zonula occludens-1 and occludin [96]
requires additional time. This also applies to the P2X7Rs induced-increase in GSK-3β (glycogen
synthase kinase 3β) protein levels that reduce the claudin-18 protein levels [94]. Inhibition of the
claudin-4 function results in marked increase in alveolar space edema [95].
Therefore, although the interstitial edema caused by capillary leakage occurs immediately after
the initialization of the pro-inflammatory response of the innate immune system the breakdown of the
tight junctions requires more time. This breakdown of the tight junctions enables the interstitial fluid
to reach the alveolar space leading to alveolar edema. This explains the observations that interstitial
edema precedes alveolar space flooding by hours [28,29] and provides the evidence that surfactant
function impairment that occurs at 2 h after the initiation of high power mechanical ventilation in
rats [22] is not caused by the disaggregation of surfactant LAs by the extravasated serum containing
serum proteins. This rather early surfactant impairment can be explained by the halted FACE-induced
trans-epithelial transport of Na+, Ca2+ and water molecules as mentioned above.
11. Surfactant Impairment Causes Changes in Alveolar Mechanics Exacerbating the Release of
Extracellular ATP
We postulate that the magnitude of the extracellular release of ATP molecules by the mechanical
deformation of the alveolar epithelial cells during continuous mandatory ventilation with high tidal
volumes and low respiratory rate is such that the capacity of the soluble and ecto-enzymes is sufficient
to maintain the extracellular ATP within the concentration range of 85 nM to well below 100 µM.
Increasing the respiratory rate to reach a mechanical power of >12 J/min boosts the extracellular
ATP release beyond the capacity of the extracellular ATPases (CD39, NPP and CD73) to clear and the
extracellular ATP levels gradually increase reaching >100 µM and >300 µM concentrations, resulting
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in surfactant impairment and VILI, respectively [10,17]. Thus, the healthy lung with intact surfactant
function can withstand a strain of 2.5 fairly well [15] as long as the extracellular ATP levels remain
below the levels that cause the desensitization of the P2Y2Rs and the PX4Rs [52,85].
Using a synchrotron refraction-enhanced computed tomography Sera, et al. (2013) showed that
in the healthy murine lung inflation of the lung by increasing the airway pressure from 0 to 8 cm
H2O changes the alveolar duct diameter and not the alveolar space dimensions. At higher airway
pressures, the alveolar ducts diameter remains constant and the alveolar space dimensions increase [97].
Therefore, despite the surfactant-induced decrease in surface tension the alveoli require adequate
pressure to increase their diameter.
In addition to pressure, time is required to inflate the alveoli [98]. This phenomenon is described
as the viscoelastic properties of lung tissue by Suki and Bates [99]. The time and the pressure that are
required to inflate the alveoli are proportional to the surface tension. The higher the alveolar surface
tension the longer the time and the higher the airway pressure that is required for the alveoli to be
inflated [98,99]. After surfactant deactivation by saline lavage, a pressure of 40 cm H2O over a 2 second
period is required to recruit 80% of collapsed alveoli and 40 s to recruit the remaining alveoli [98].
At lower pressures and shorter time intervals, alveoli are not recruited as tidal volume is redistributed
towards the alveolar ducts causing a tremendous enlargement of their size [100]. The dramatic increase
in the alveolar duct diameter can be explained by the fact that there are 480 million alveoli [101] and
5600 acinar airways including the alveolar ducts [102] with an alveolar:alveolar duct ratio of 2.9 [100].
Redistribution of the tidal volume from the alveoli into the alveolar ducts results in extremely dilated
alveolar ducts and pathologic stretching of the alveolar walls of the adjacent alveoli [100].
Moreover, alveoli are not only subject to the viscoelastic properties of the lung during inflation,
but also during deflation. Satalin, et al. (2016) reported in a surfactant-deactivated lung that
there is a lag time of 0.17 s before alveoli begin to collapse after the termination of the inspiratory
phase. Furthermore, it takes 0.25 s before the alveoli fully collapse (Figure 3) [103]. This study
demonstrated that the very short expiratory duration using the time-controlled adaptive ventilation
(TCAV) protocol (corresponding with the APRV75% group in Figure 4) is critical in normalizing
air distribution within the alveoli and alveolar duct in a rat Tween-induced ARDS model and is
supported the study by Kollisch-Singule, et al. (2014) and illustrated in Figure 4 [100]. If the
expiratory duration is longer than the alveolar collapse-time, these newly recruited alveoli will
derecruit with each expiration (Figures 3 and 4); if set shorter than the alveolar collapse-time the alveoli
will remain inflated during the brief expiration period (Figures 3 and 4) [100]. Thus, the TCAV protocol
stabilizes alveoli by two mechanisms: pressure and time. Therefore, although ventilation with low
mechanical power (<12 J/min) does not cause lung injury in healthy lung [15], ventilation with very
low mechanical power corresponding with a tidal volume of 6 mL/kg ideal body weight is injurious
for the surfactant-deactivated lung (Figure 3) [100,104]. The efficacy of the TCAV protocol was recently
demonstrated in experimental pulmonary and extrapulmonary ARDS [105]. The DAD score (reflecting
the extent of pulmonary damage) and the expression of biological markers for lung tissue damage (i.e.,
amphiregulin, vascular cell adhesion molecule 1—VCAM-1, syndecan 1, metalloproteinase 9—MMP9
and decorin) are significantly higher in volume controlled ventilation (VC) with 8 mL/kg ideal body
weight than in TCAV [105].
In this perspective, the consequences of mechanical ventilation on the surfactant-deactivated lung
are: First, if the pressure and the duration of the inspiration are inadequate to expand the alveoli tidal
volume will be distributed towards the alveolar ducts. This increases the deformation of the alveolar
epithelial cells of the adjacent alveoli that are connected to these alveolar ducts tremendously and
augments the release of extracellular ATP to a level beyond the capacity of the ATPase enzymes (CD39,
NPP and CD 73). ATP will gradually reach >100 µM concentrations causing surfactant impairment and
>300 µM concentrations invoking the pro-inflammatory response of the innate immune system injuring
the lung tissue. Bellingan, et al. (2014) reported that treatment with interferon-beta-1a (IFN-β-1a) that
up-regulates the expression of CD73 reduces the ARDS mortality [106]. Second, even after a successful
Int. J. Mol. Sci. 2018, 19, 1185 12 of 19
recruitment maneuver (RM) the newly recruited alveoli will collapse and reopen during every breath
if PEEP is not set correctly since the expiratory duration with continuous mandatory ventilation is
longer than the alveolar collapse-time.
The difficulty of opening the lung with a RM and attempting to stabilize it with PEEP was
demonstrated in a recent publication by Cavalcanti, et al. (2017) and the “the Alveolar Recruitment
for Acute Respiratory Distress Syndrome Trial (ART) Investigators” [107]. They reported a study of
patients with moderate to severe ARDS. The patients are randomized into a control and an experimental
treatment group. The control arm received ventilation with low tidal volume according to the ARDSNet
protocol. The experimental strategy arm received the same low tidal volume protocol as the control
group with the addition of neuromuscular blockade and RMs with incremental PEEP up to plateau
pressure levels of 50 cm H2O followed by a decremental PEEP trial to identify the PEEP level with the
highest respiratory compliance. The mean PEEP level in the control group was 12.2 cm H2O and 16.8 cm
H2O in the experimental group. The mean plateau pressure in the experimental group was higher than
in the control group but was always below 30 cm H2O. There is a slight but statistically significant
higher mortality in the experimental group compared to the control group (55.3% vs. 49.3%) [107].
The RMs in the treatment group may open the lung initially, but soon after the termination of the RMs,
the newly recruited alveoli recollapse due to an inadequate PEEP level. Therefore, the investigators
opened up the lungs during the RM but the level of PEEP failed to keep the lung open thereafter,
providing one explanation for the lack of benefit observed in the experimental group.
Figure 3. Graphic presentation of the time course of alveolar collapse during the expiration by
releasing an airway pressure of 25 cm H2O to zero as depicted by in-vivo microscopy in rats with
surfactant-deactivated lung. The Y-axis represents the alveolar surface areas in pixels and the X-axis is
the time. There is a time lag of 0.17 s before alveoli start to collapse after the initiation of the expiratory
phase. Furthermore, it takes 0.25 s before the alveoli are fully collapsed. Figure from Satalin, et al.
(2016) [103], presented at ‘The Open Forum Sessions’ during the AARC Congress 2016.
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Figure 4. The effect of the ventilator settings on the alveolar mechanics. The left graphics are schematic
presentations of the ventilator pressure-time curves belonging to the photomicrographs of the lung
presented on the right figure. The lung was fixed at the end-inspiratory pressure (left column of
the photomicrographs) and at the end-expiratory pressure (right column of the photomicrographs).
The conducting airspaces including the alveolar ducts are colored green, the alveolar spaces are magenta
and the alveolar walls are lilac. In APRV75% and APRV10% termination of the expiration is set at an
EEF/PEF ratio of 75% and 10%, respectively. In the healthy lung using tissue microscopy after fixing
the lung at peak-inspiration and at end-expiration, Kollisch-Singule, et al. (2014) demonstrated that
the distribution of tidal volume between the alveoli and the alveolar ducts shows little change during
inspiration and expiration (‘control’) [100]. After surfactant deactivation, there is a redistribution of air
at the end of expiration from the alveoli towards the alveolar ducts (‘expiration’ and ‘PEEP 5’). During
inspiration, the redistribution towards the alveolar ducts markedly increases causing a tremendous
deformation of the alveoli adjacent to these alveolar ducts (‘inspiration’ and ‘PEEP 5’). This results in
an increased microstrain (defined as the change in length of the alveolar ducts between inspiration
and expiration normalized by their original length). Increasing the PEEP level to 16 cm H2O decreases
the microstrain but not the redistribution of air towards the alveolar ducts (‘Inspiration’, ‘expiration’
and ‘PEEP 16’). The application of APRV10% with a Phigh of 40 cm H2O and expiratory time of
0.22–0.26 s increases the redistribution of air towards the alveolar ducts and the microstrain dramatically
(‘Inspiration’, ‘expiration’ and ‘APRV10%’). By applying APRV75% with a Phigh of 40 cm H2O with
a shorter expiration time 0f 0.04 to 0.08 s the redistribution of air towards the alveolar ducts and
the microstrain much improve but are still not completely restored (‘Inspiration’, ‘expiration’ and
‘APRV75%’) [100]. Thus: in surfactant deactivated lung, a short expiratory time stabilizes the alveoli
and a long expiratory time allows alveolar collapse to occur. By setting the timing of the termination of
the expiration relative the PEF, the actual expiration time will change proportional to the time-constant
of the alveoli. For instance, in slowly deflating alveoli a longer time is required to reach an EEF/PEF
ratio of 75% than in fast deflating alveoli. Consequently, the expiration time in a lung with a high
compliance is longer than in a lung with a low compliance. Therefore, this mode is now referred
to as the ‘time-controlled adaptive ventilation’ (TCAV). APRV: airway pressure release ventilation;
EEF: end-expiratory flow; PEF: peak-expiratory flow; Phigh: inspiratory pressure; PEEP: positive end
expiratory pressure; Vt: tidal volume; RR: respiratory rate; Exp: Expiratory. Photomicrographs figure
from Kollisch-Singule, et al. (2014) [100] with permission.
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12. Summary and Conclusions
In the healthy lung, continuous mandatory ventilation with high mechanical power causes
an increase in mechanical deformation of the AT I cells followed by an increase in the release of
extracellular ATP. This then functions as a signaling molecule for the AT II cells to release surfactant.
However, at about 100 µM concentrations, extracellular ATP receptors of the AT II cells become
desensitized, surfactant release is halted, and the FACE-induced trans-epithelial transport of Na+,
Ca2+, and water molecules from the alveolar space to the interstitium is diminished, thickening
the alveolar liquid lining and impairing the surfactant function. At 300 µM concentrations and
above, extracellular ATP initiates the pro-inflammatory response of the innate immune system with
immediate increased complement C3 levels causing capillary leakage followed by the disruption of the
intercellular junctions of the alveolar epithelial cells, causing overt alveolar space edema. Surfactant
disaggregation by serum proteins further deactivates the surfactant function, leading to a significant
alteration in the viscoelastic properties of the lung and the redistribution of the tidal volume towards
the alveolar ducts. This boosts the extracellular release of ATP by the alveolar epithelial cells and the
pro-inflammatory response of the innate immune system. In addition, the initiated pro-inflammatory
response of the innate immunity injuring the lung is followed by a reactive adenosynergic immune
paralysis of the immune system and fibrosis [10]. Although extracellular ATP levels can be reduced by
a treatment with IFN-β-1a, this may increase adenosine levels.
Future research should be directed into blocking high levels of extracellular ATP combined with
improved ventilation strategies. Furthermore, new monitoring systems have to be developed to assess
markers of the massively increased purinergic signaling in the lung.
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